Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 7 min ago
Peer-reviewedCC BY-NCAging medicine (Milton (N.S.W))

Blood-Based Biomarkers in Alzheimer's Disease: Advances in Detection Technologies and Clinical Applications.

  • Shuangshuang Li1
  • Lin Huang2
  • Qihao Guo1,2
  1. 1School of International Medical Technology Shanghai Sanda University Shanghai China.
  2. 2Department of Gerontology Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Read full textPDFDOICite

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder. Irreversible pathological alterations are already present when clinical symptoms emerge. Therefore, early diagnosis and intervention are crucial for improving patient outcomes and reducing the social and healthcare burden. With its advantages of minimal invasiveness, convenience, affordability, and high accessibility, blood-based testing has overcome the limitations of conventional methods, becoming a major focus of research in early AD diagnosis in recent years. Based on the key domestic and international research findings in recent years, this paper systematically reviews the types, mechanisms of action, and relevant detection technologies of blood-based biomarkers for AD.

Related

  1. Advances in CRISPR‐based detection technologies for severe fever with thrombocytopenia syndrome virus (Dabiebanda virus): A mini review
    Junhu Wang, Changqiang Zhu, Jinzhao Chu +6
    Clinical and Translational DiscoveryPeer-reviewedCC BYFull textInfectious diseaseDOAJ
  2. Recent advances in bacterial detection techniques targeting genetic, protein, and enzymatic biomarkers
    Hanren Chen, Jiayi Xiao, Bihong Diao +3
    Journal of Pharmaceutical AnalysisPeer-reviewedCC BYFull text5 citedPharmacology & toxicologyDOAJ
  3. Editorial: Advances and challenges in orbital imaging: from radiography to modern MRI and 3D technologies
    Alon Kahana, Alon Kahana
    Frontiers in OphthalmologyPeer-reviewedCC BYFull textGeneral medicineDOAJ
  4. Advances in Diagnostic Testing for Eosinophilic Esophagitis: Current Approaches, Limitations, and Emerging Technologies
    Maanasa Naga Laxmi Pulavarty, Amy Meehan, Cary Qualia
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Vulnerable Coronary Plaques on CT Angiography: Imaging Biomarkers, Artificial Intelligence, and Emerging Technologies for Risk Stratification
    Alin Horatiu Nedelcu, Emil Anton, Ancuta Lupu +12
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{li2026bloodbased,
  title = {{Blood-Based Biomarkers in Alzheimer's Disease: Advances in Detection Technologies and Clinical Applications.}},
  author = {Shuangshuang Li and Lin Huang and Qihao Guo},
  journal = {Aging medicine (Milton (N.S.W))},
  year = {2026},
  month = oct,
  doi = {10.1002/agm2.70112},
  url = {https://europepmc.org/article/MED/42948835},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Blood-Based Biomarkers in Alzheimer's Disease: Advances in Detection Technologies and Clinical Applications.
AU  - Shuangshuang Li
AU  - Lin Huang
AU  - Qihao Guo
PY  - 2026
DA  - 2026/10/27
JO  - Aging medicine (Milton (N.S.W))
DO  - 10.1002/agm2.70112
UR  - https://europepmc.org/article/MED/42948835
AB  - Alzheimer's disease (AD) is a neurodegenerative disorder. Irreversible pathological alterations are already present when clinical symptoms emerge. Therefore, early diagnosis and intervention are crucial for improving patient outcomes and reducing the social and healthcare burden. With its advantages of minimal invasiveness, convenience, affordability, and high accessibility, blood-based testing has overcome the limitations of conventional methods, becoming a major focus of research in early AD diagnosis in recent years. Based on the key domestic and international research findings in recent years, this paper systematically reviews the types, mechanisms of action, and relevant detection technologies of blood-based biomarkers for AD.
SN  - 2475-0360
ER  -